{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:23:42Z","timestamp":1789381422997,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1002\/jps.23413","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T19:15:50Z","timestamp":1355253350000},"page":"341-346","source":"Crossref","is-referenced-by-count":17,"title":["Enhanced Oral Absorption of Ibandronate via Complex Formation with Bile Acid Derivative"],"prefix":"10.1016","volume":"102","author":[{"given":"Jin Woo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Rim","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ok-Cheol","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Tae","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1002\/jps.23413_bb0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"issue":"2 Suppl","key":"10.1002\/jps.23413_bb0015","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.amjmed.2008.12.003","article-title":"Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis","volume":"122","author":"Bilezikian","year":"2009","journal-title":"Am J Med"},{"issue":"9","key":"10.1002\/jps.23413_bb0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muhlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1002\/jps.23413_bb0025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1002\/jps.23413_bb0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1002\/jps.23413_bb0035","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","article-title":"Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO)","volume":"21","author":"Emkey","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1002\/jps.23413_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1002\/jps.23413_bb0045","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1002\/jps.23413_bb0050","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: A clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1002\/jps.23413_bb0055","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.clinthera.2004.12.010","article-title":"Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials","volume":"26","author":"Tripathy","year":"2004","journal-title":"Clin Ther"},{"issue":"5","key":"10.1002\/jps.23413_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejcsup.2004.01.003","article-title":"Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease","volume":"2","author":"Leyland-Jones","year":"2004","journal-title":"Eur J Cancer Suppl"},{"issue":"4","key":"10.1002\/jps.23413_bb0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF02556218","article-title":"Sodium EDTA enhances intestinal absorption of two bisphosphonates","volume":"49","author":"Janner","year":"1991","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1002\/jps.23413_bb0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1773-2247(11)50084-X","article-title":"Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women","volume":"21","author":"McIntyre","year":"2011","journal-title":"J Drug Deliv Sci Tec"},{"issue":"3","key":"10.1002\/jps.23413_bb0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00125-004-1658-2","article-title":"A new drug carrier, N-alpha-deoxycholyl-l-lysyl-methylester, for enhancing insulin absorption in the intestine","volume":"48","author":"Lee","year":"2005","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/jps.23413_bb0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/mp9002688","article-title":"Diabetes correction in pancreatectomized canines by orally absorbable insulin\u2013deoxycholate complex","volume":"7","author":"Kim","year":"2010","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1002\/jps.23413_bb0085","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1002\/jps.23413_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jconrel.2007.07.013","article-title":"Liphophilic complexation of heparin based on bile acid for oral delivery","volume":"123","author":"Lee","year":"2007","journal-title":"J Control Release"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915312430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915312430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T18:31:47Z","timestamp":1655317907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915312430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0022354915312430"],"URL":"https:\/\/doi.org\/10.1002\/jps.23413","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}